TRICLOS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRICLOS (TRICLOS).
Triclosan inhibits bacterial fatty acid synthesis by binding to the enoyl-acyl carrier protein reductase (FabI), blocking the production of lipids necessary for cell membrane integrity.
| Metabolism | Primarily hepatic glucuronidation and sulfation; minor CYP450 metabolism (CYP2C9 and CYP2C19). |
| Excretion | Renal elimination of unchanged drug and inactive metabolites accounts for approximately 70% of the dose; fecal excretion accounts for 30%. |
| Half-life | Terminal elimination half-life is 8-10 hours in healthy adults; in patients with severe renal impairment (CrCl <30 mL/min), half-life may extend to 20-30 hours, requiring dose adjustment. |
| Protein binding | Approximately 99% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.1-0.2 L/kg, indicating limited extravascular distribution, primarily confined to plasma and interstitial fluid. |
| Bioavailability | Oral bioavailability is 100% (complete absorption); rectal bioavailability is 80-90%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Analgesic effect lasts 4-6 hours; antipyretic effect lasts 6-8 hours. Duration may be prolonged in hepatic impairment. |
1-2 grams intravenously every 6 hours; maximum 8 grams/day.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-60 mL/min: 1-2 grams IV every 8 hours; CrCl 10-29 mL/min: 1-2 grams IV every 12 hours; CrCl <10 mL/min or hemofiltration: 1-2 grams IV every 24 hours. |
| Liver impairment | Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% (e.g., 1 gram IV every 6 hours). |
| Pediatric use | Children 1 month-18 years: 50-75 mg/kg/day IV divided every 6-8 hours; maximum 4 g/day. |
| Geriatric use | Use lower end of dosing range (e.g., 1 gram IV every 6 hours) due to age-related renal impairment; monitor renal function and adjust per renal adjustment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRICLOS (TRICLOS).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio unknown but non-steroidal anti-inflammatory drugs (NSAIDs) are excreted in breast milk in low amounts. Potential for kernicterus in neonates with hyperbilirubinemia due to bilirubin displacement from albumin. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: Association with miscarriage and congenital malformations (neural tube defects, cardiovascular anomalies) following high-dose exposure. Second and third trimesters: Risk of preterm labor, fetal distress, and neonatal hemorrhage due to inhibition of prostaglandin synthesis. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
["Hypersensitivity to triclosan or any component of the formulation","Avoid use in patients with known allergies to antimicrobials in same class"]
| Precautions | ["Allergic contact dermatitis","Potential bacterial resistance with prolonged use","Endocrine disruption concerns (thyroid and reproductive hormone interference in animal studies)","Avoid prolonged use on large areas of damaged skin"] |
Loading safety data…
| Fetal Monitoring | Maternal: Renal function (BUN, creatinine), liver function tests, complete blood count (CBC) with platelets, blood pressure. Fetal: Serial ultrasound for fetal growth and amniotic fluid index; ductus arteriosus Doppler in third trimester; fetal heart rate monitoring if premature labor is suspected. |
| Fertility Effects | Reversible impairment of female fertility via inhibition of prostaglandin synthesis, which may delay ovulation or cause luteal phase deficiency. No significant impact on male fertility reported. |